NCT03179904 2026-02-24
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Mayo Clinic
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT07407920 2026-02-12
Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05408845 2026-01-14
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NRG Oncology
Phase 2 Recruiting